TABLE 5.
Patient no. | Time after birth (wk) | Onsetb | IgG level (IU/ml) | Cutoffc
|
IgM Rec-ELISA cutoffd
|
||
---|---|---|---|---|---|---|---|
ELFA-Toxo-IgM | ETI-TOXOK-M | GST-EC2 | GST-EC3 | ||||
T1 | 1 | B | 169 | 6.41 | 2.66 | 2.479 | 0.542 |
T2 | 2 | B | 988 | 0.73 | 0.15 | 0.360 | 0.270 |
T3 | 2 | Sub | 300 | 0.09 | 0.13 | 0.212 | 0.209 |
T4 | 3 | Sub | 57 | 0.05 | 0.23 | 0.206 | 0.211 |
T5 | 3 | Sub | 124 | 0.13 | 1.62 | 0.641 | 1.103 |
T6 | 4 | Sub | 218 | 0.04 | 0.09 | 0.452 | 0.269 |
T7 | 4 | S | 157 | 2.61 | 1.62 | 1.522 | 0.225 |
T8 | 4 | S | 172 | 3.98 | 1.50 | 1.804 | 0.353 |
T9 | 5 | S | 1147 | 0.07 | 0.10 | 0.519 | 0.206 |
T10 | 5 | B | 47 | 0.11 | 0.12 | 0.272 | 0.276 |
T11 | 6 | Sub | 28 | 0.10 | 0.18 | 2.617 | 0.731 |
T12 | 6 | Sub | 136 | 0.07 | 0.11 | 0.314 | 0.216 |
T13 | 7 | S | 209 | 0.88 | 0.47 | 0.683 | 0.217 |
T14 | 8 | Sub | 43 | 0.06 | 0.07 | 0.196 | 0.213 |
T15 | 8 | B | 160 | 0.82 | 0.08 | 0.206 | 0.219 |
T16 | 8 | B | 64 | 0.02 | 0.40 | 0.231 | 0.228 |
T17 | 8 | Sub | 145 | 0.31 | 0.57 | 0.985 | 0.314 |
T18 | 9 | Sub | 300 | 6.37 | 1.30 | 0.548 | 0.315 |
T19 | 12 | Sub | 196 | 0.05 | 0.17 | 0.463 | 0.268 |
T20 | 12 | Sub | 75 | 0.05 | 0.07 | 0.237 | 0.222 |
Serum samples (samples T1 to T20) were analyzed by IgM Rec-ELISAs with GST-EC2 and GST-EC3 antigens or by commercial assays (ELFA-IgM and ETI-TOXO-M).
Severity of clinical onset: S, severe; B, benign; Sub, subclinical.
The cutoff values for the ELFA-IgM and ETI-TOXO-M assays were 0.65 and 0.41, respectively, as indicated by manufacturers. Boldface type, values greater than the cutoff value.
The cutoff values for the IgM Rec-ELISA with the GST-EC2 and GST-EC3 antigens, calculated with sera from uninfected infants (n = 10), were 0.25 and 0.26, respectively. Boldface type, values greater than the cutoff value.